 To carry out this study, 24 moderate CD patients will be enrolled in a safety phase 2a study. CD patients will be included after intestinal resection surgery or in moderate Crohns Disease CD. Drug therapy will consisted in 3 injections of 100 μg of P28GST within 3 months one injection per month. The main objective of this study is to follow-up monthly rate and seriousness of adverse events during one year. Secondary objectives are to control immunologic and inflammatory blood and tissue markers, appearance or not of a clinical recurrence assessed by CDAI Crohn Disease Activity Index. 